854 related articles for article (PubMed ID: 28659180)
1. Multiparametric imaging for detection and characterization of hepatocellular carcinoma using gadoxetic acid-enhanced MRI and perfusion-CT: which parameters work best?
Kurucay M; Kloth C; Kaufmann S; Nikolaou K; Bösmüller H; Horger M; Thaiss WM
Cancer Imaging; 2017 Jun; 17(1):18. PubMed ID: 28659180
[TBL] [Abstract][Full Text] [Related]
2. Differences Between CT-Perfusion and Biphasic Contrast-enhanced CT for Detection and Characterization of Hepatocellular Carcinoma: Potential Explanations for Discrepant Cases.
Perl RM; Portugall J; Hinterleitner C; Hinterleitner M; Kloth C; Walter SS; Bitzer M; Horger MS
Anticancer Res; 2021 Mar; 41(3):1451-1458. PubMed ID: 33788737
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
4. Characterization of hepatocellular carcinoma (HCC) lesions using a novel CT-based volume perfusion (VPCT) technique.
Kaufmann S; Horger T; Oelker A; Kloth C; Nikolaou K; Schulze M; Horger M
Eur J Radiol; 2015 Jun; 84(6):1029-35. PubMed ID: 25816994
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid.
Besa C; Lewis S; Pandharipande PV; Chhatwal J; Kamath A; Cooper N; Knight-Greenfield A; Babb JS; Boffetta P; Padron N; Sirlin CB; Taouli B
Abdom Radiol (NY); 2017 Jan; 42(1):179-190. PubMed ID: 27448609
[TBL] [Abstract][Full Text] [Related]
6. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
[TBL] [Abstract][Full Text] [Related]
7. Multiphasic Dynamic Computed Tomography Evaluation of Liver Tissue Perfusion Characteristics Using the Dual Maximum Slope Model in Patients With Cirrhosis and Hepatocellular Carcinoma: A Feasibility Study.
Lee DH; Lee JM; Klotz E; Han JK
Invest Radiol; 2016 Jul; 51(7):430-4. PubMed ID: 26756941
[TBL] [Abstract][Full Text] [Related]
8. Imaging features of hepatic sarcomatous carcinoma on computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
Gu KW; Kim YK; Min JH; Ha SY; Jeong WK
Abdom Radiol (NY); 2017 May; 42(5):1424-1433. PubMed ID: 28078380
[TBL] [Abstract][Full Text] [Related]
9. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
[TBL] [Abstract][Full Text] [Related]
10. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
[TBL] [Abstract][Full Text] [Related]
11. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
[TBL] [Abstract][Full Text] [Related]
12. Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.
Orlacchio A; Chegai F; Fabiano S; Merolla S; Funel V; Di Giuliano F; Manuelli M; Tisone G; Francioso S; Angelico M; Palmieri G; Simonetti G
Radiol Med; 2016 Jul; 121(7):588-96. PubMed ID: 27100719
[TBL] [Abstract][Full Text] [Related]
13. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma with central scar on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging.
Han SB; Kim YK; Min JH; Ha SY; Jeong WK; Lee WJ
Acta Radiol; 2018 Apr; 59(4):393-401. PubMed ID: 28760004
[TBL] [Abstract][Full Text] [Related]
15. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
[TBL] [Abstract][Full Text] [Related]
16. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging?
Kim YK; Kim CS; Han YM; Park G
Invest Radiol; 2010 Nov; 45(11):740-6. PubMed ID: 20644488
[TBL] [Abstract][Full Text] [Related]
17. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
[TBL] [Abstract][Full Text] [Related]
18. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Angiomyolipoma Versus Hepatocellular Carcinoma in the Noncirrhotic Liver on Gadoxetic Acid-Enhanced MRI: A Diagnostic Challenge.
Lee SJ; Kim SY; Kim KW; Kim JH; Kim HJ; Lee MG; Yu ES
AJR Am J Roentgenol; 2016 Sep; 207(3):562-70. PubMed ID: 27248975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
